DURECT

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DURECT reports robust revenue growth and advances AHFIRM trial

DURECT's financials improved notably in 2022, driven by milestone payments and revenue growth.
AHFIRM trial progress and potential of larsucosterol offer promising prospects for the company.
Balancing high R&D costs, regulatory milestones, and market competition are key challenges.
Strategic management of cash reserves and successful trial outcomes are critical for future success.

DURECT (DRRX) advances promising AH treatment with strong Q1 results

DURECT's Q1 performance reflects progress in the development of Larsucosterol for AH.
Strengths lie in positive clinical data, regulatory support, and market awareness.
Challenges include market recall, pricing strategy, and potential dosing issues.
Opportunities exist in market expansion, regulatory milestones, and cost-saving potential.

DURECT reports Q2 revenue, progresses AHFIRM trial, eyes oncology expansion

DURECT's Q2 2023 performance reflects a balance between revenue generation, strategic investments, and financial strengthening.
The company's strengths lie in advancing clinical trials, exploring new markets, and planning for commercial success.
Challenges include regulatory hurdles, financial sustainability, and addressing analyst inquiries, while opportunities abound in oncology expansion and market growth.
Overall, DURECT's focus on innovation, strategic partnerships, and market awareness positions it for future success and growth.

DURECT reports positive trial results for larsucosterol in AH

DURECT's financials and cash position remain stable, with a successful net proceeds raise and operational funding secured.
Larsucosterol's positive trial results and FDA Fast Track designation position it as a promising treatment for AH.
While challenges exist in regulatory pathways and trial complexities, the market potential for larsucosterol is substantial.
Overall, DURECT's focus on addressing AH with an effective treatment underscores its commitment to patient care.

DURECT reports revenue decline but positive trial results for larsucosterol

DURECT saw a decline in revenues but managed to reduce R&D and SG&A expenses in 2023.
Positive trial results and feedback position larsucosterol as a promising therapy for alcohol-associated hepatitis.
Navigating revenue challenges, regulatory discussions, and cost management are key focus areas for DURECT.

DURECT reports Q1 revenue dip, eyes FDA approval for AH treatment

DURECT's Q1 2024 performance saw revenue decline but cost management improvements.
Progress in larsucosterol Phase III trial and AHFIRM data acceptance signal positive developments.
While revenue challenges persist, opportunities in AH treatment market and financial stability are notable.
Strategic focus on AH patients' needs and efficient trial design position DURECT for future success.

DURECT reports revenue growth and progress in life-saving therapy trials

DURECT's Q2 2024 performance showed revenue growth and significant expense reductions.
Strengths lie in breakthrough therapy designation, positive study results, and cost-efficient trial planning.
Challenges include managing cash burn, meeting trial timelines, and industry competition.
Opportunities exist in market expansion, partnerships, pipeline diversification, and cost optimization.

DURECT reports improved Q3 financials and progresses key clinical trials

DURECT's financials improved in Q3 2024 with lower expenses and stable revenues, while advancing key clinical trials.
Despite challenges like licensing agreement termination, the company is poised for growth with promising trial results and strategic opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DURECT Corporation (NASDAQ:DRRX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jim Brown - Co-Founder, Chief Executive Officer, President, Director Tim Papp - Chief Financial Officer WeiQi Lin - Executive Vice President of Research and Development, Principal Scientist Conference Call Participants Thomas Yip - H.C. Wainwright Karl Burns - Northland Capital Markets Operator Greetings!

DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript

Durect (DRRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.40 per share a year ago.

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

-     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif.

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

CUPERTINO, Calif. , Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024.

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update

CUPERTINO, Calif. , Oct. 17, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024, organized by the American Association for the Study of Liver Diseases (AASLD), to be held November 15-19, 2024 in San Diego, California.

DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024

- Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation  - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of larsucosterol reduced 90-day mortality in U.S. patients by 57% and 58%, respectively, compared with placebo CUPERTINO, Calif. , Sept. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today provided details on the design of its upcoming registrational Phase 3 trial which will evaluate larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH).

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis

CUPERTINO, Calif. , Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C.

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

DURECT Corporation (NASDAQ:DRRX ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Tim Papp - CFO & Secretary Jim Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer Ed Arce - H.C. Wainwright Carl Byrnes - Northland Capital Markets Operator Ladies and gentlemen, welcome to the DURECT Corporation Second Quarter 2024 Earnings Conference Call.

DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript

Durect (DRRX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago.

Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates

-         FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis -         Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design -         Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 -         Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif.

DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update

CUPERTINO, Calif. , Aug. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August 13, 2024.

DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update

Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.

Are Medical Stocks Lagging DURECT (DRRX) This Year?

DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial  CUPERTINO, Calif. , May 21, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH).

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation (NASDAQ:DRRX ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Timothy M. Papp - CFO James E.

DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript

Durect (DRRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.52 per share a year ago.

Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

-         FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis -         Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif.

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update

CUPERTINO, Calif. , May 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its first quarter financial results on Monday, May 13, 2024.

DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update

CUPERTINO, Calif. , April 30, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2024 to take place June 5-8, 2024 in Milan, Italy.

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis

Durect (DRRX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.46 per share a year ago.

Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates

DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript

- Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif.

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CUPERTINO, Calif. , March 20, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024.

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly market and commercialize the ALZET product line to customers over a multi-year period CUPERTINO, Calif. , March 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET® Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Aadi Bioscience

Kintara Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

News for DURECT Stock (DRRX)